EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppressesmutated breast cancer
Yazarlar (10)
Elif Asik The University Of Texas Md Anderson Cancer Center
Dr. Öğr. Üyesi Yeliz AKPINAR Kırşehir Ahi Evran Üniversitesi, Türkiye
Ayşe Caner Ege Üniversitesi, Türkiye
Nermin Kahraman The University Of Texas Md Anderson Cancer Center
Tulin Guray
Middle East Technical University (Metu)
Middle East Technical University (Metu)
Murvet Volkan
Middle East Technical University (Metu)
Middle East Technical University (Metu)
Constance Albarracin
The University Of Texas Md Anderson Cancer Center
The University Of Texas Md Anderson Cancer Center
Apar Pataer
The University Of Texas Md Anderson Cancer Center
The University Of Texas Md Anderson Cancer Center
Banu Arun
The University Of Texas Md Anderson Cancer Center
The University Of Texas Md Anderson Cancer Center
Bulent Ozpolat
The University Of Texas Md Anderson Cancer Center
The University Of Texas Md Anderson Cancer Center
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Nanomedicine (Q1) | ||
| Dergi ISSN | 1743-5889 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 09-2019 |
| Kabul Tarihi | 12-04-2026 | Yayınlanma Tarihi | – |
| Cilt / Sayı / Sayfa | 14 / 17 / 2315–2338 | DOI | 10.2217/nnm-2019-0132 |
| Makale Linki | https://www.futuremedicine.com/doi/10.2217/nnm-2019-0132 | ||
| Özet |
| Aim To investigate the role of EF2K in BRCA1-mutated breast cancer. Materials & methods We developed silica coated cobalt-ferrite (CoFe) nanoparticles for in vivo delivery of small interfering RNAs (siRNAs) into BRCA1-mutated breast cancer. Results Expression of EF2K is highly upregulated in the majority (78.5%) of BRCA1-mutated patients and significantly associated with poor patient survival and metastasis. Silencing of EF2K reduced cell proliferation, migration and invasion of the cancer cells. In vivo therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained EF2K gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer. Conclusion EF2K is a potential novel molecular target in BRCA1-mutated tumors and CoFe-based siRNA nanotherapy may be used as a novel approach to target EF2K. |
| Anahtar Kelimeler |
| angiogenesis | BRCA1 | breast cancer | EF2 kinase | gene-silencing therapy | invasion | metastasis | migration | nanoparticles | PARP inhibitor |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 24 |
| Scopus | 2 |
| Web of Science | 16 |